Pseudocholinesterase and serum lipoproteins

Schouten, J.A.; Mulder, Cees; Beynen, A.C.

doi:10.1016/0021-9150(87)90288-7

“…The effect of pravastatin in lowering LDL-TG can be attributed to up-regulation of apoB\E receptor activity, resulting in enhanced clearance of LDL. Pravastatin treatment did not affect PChE activity, confirming an earlier report [29], and induced a moderate increase in HbA " c levels, while bezafibrate treatment induced decreases in both fasting glucose and HbA " c. These changes could not be attributed to changes in body weight or insulin dose.…”

Section: Discussionsupporting

confidence: 88%

Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?

Rustemeijer

¹

,

Schouten

²

,

Voerman

³

et al. 2001

View full text Add to dashboard Cite

Hypertriglyceridaemia is a risk factor for cardiovascular disease in patients suffering from Type II diabetes mellitus, and is due to enhanced synthesis and/or impaired clearance of triacylglycerol-rich lipoproteins. In the present study we investigated whether pseudocholinesterase (PChE) activity could serve as a marker for the rate of triacylglycerol synthesis in these patients. Patients were stratified according to their apolipoprotein E (apoE) phenotype, i.e. E3E2, E3E3 or E3E4. In study I, the relationship between PChE activity and serum triacylglycerols was investigated in 224 insulin-treated patients with Type II diabetes. In study II, which had a cross-over design, PChE activity was measured in 45 dyslipidaemic, insulin-treated patients with Type II diabetes that were treated with bezafibrate or pravastatin. In study I, PChE activity was correlated positively with serum triacylglycerol concentrations, but did not differ significantly between apoE phenotypes. The strongest relationship was found in the E3E4 group (r=0.50; P=0.001), the phenotype for which hypertriglyceridaemia is expected to be the result of increased triacylglycerol synthesis. In a stepwise multiple regression analysis, serum triacylglycerol concentrations were found to be the strongest predictor of PChE activity in the E3E4 group. In study II, PChE activity decreased as a result of bezafibrate treatment in all three apoE groups. The decrease in PChE activity with bezafibrate treatment paralleled the decrease in serum triacylglycerol concentrations in the apoE subgroups. Pravastatin treatment did not significantly affect PChE activity. Thus the present study suggests an association between PChE activity and the rate of triacylglycerol synthesis. Measurement of PChE activity may therefore be a useful tool in the choice of drug for treatment of hypertriglyceridaemia in patients with Type II diabetes.

show abstract

“…Pravastatin treatment did not affect PChE activity, confirming an earlier report [29], and induced a moderate increase in HbA " c levels, while bezafibrate treatment induced decreases in both fasting glucose and HbA " c. These changes could not be attributed to changes in body weight or insulin dose. PChE activity was lowered by bezafibrate treatment in all three apoE isoform groups.…”

Section: Discussionsupporting

confidence: 87%

Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?

RUSTEMEIJER¹,

SCHOUTEN²,

VOERMAN³

et al. 2001

Self Cite

View full text Add to dashboard Cite

Hypertriglyceridaemia is a risk factor for cardiovascular disease in patients suffering from Type II diabetes mellitus, and is due to enhanced synthesis and/or impaired clearance of triacylglycerol-rich lipoproteins. In the present study we investigated whether pseudocholinesterase (PChE) activity could serve as a marker for the rate of triacylglycerol synthesis in these patients. Patients were stratified according to their apolipoprotein E (apoE) phenotype, i.e. E3E2, E3E3 or E3E4. In study I, the relationship between PChE activity and serum triacylglycerols was investigated in 224 insulin-treated patients with Type II diabetes. In study II, which had a cross-over design, PChE activity was measured in 45 dyslipidaemic, insulin-treated patients with Type II diabetes that were treated with bezafibrate or pravastatin. In study I, PChE activity was correlated positively with serum triacylglycerol concentrations, but did not differ significantly between apoE phenotypes. The strongest relationship was found in the E3E4 group (r=0.50; P=0.001), the phenotype for which hypertriglyceridaemia is expected to be the result of increased triacylglycerol synthesis. In a stepwise multiple regression analysis, serum triacylglycerol concentrations were found to be the strongest predictor of PChE activity in the E3E4 group. In study II, PChE activity decreased as a result of bezafibrate treatment in all three apoE groups. The decrease in PChE activity with bezafibrate treatment paralleled the decrease in serum triacylglycerol concentrations in the apoE subgroups. Pravastatin treatment did not significantly affect PChE activity. Thus the present study suggests an association between PChE activity and the rate of triacylglycerol synthesis. Measurement of PChE activity may therefore be a useful tool in the choice of drug for treatment of hypertriglyceridaemia in patients with Type II diabetes.

show abstract

“…butyrylcholine, increases with the increased availability of unesterified fatty acids in the liver, or with enhanced lipogenesis due to dietary intake of carbohydrate-rich food. In addition, some authors found that serum BuChE activity positively correlated with serum triglyceride concentrations in hypertensive [8], obese [2], and dyslipidemic patients [9,10,11]. An observation has been reported of serum lipoproteins and BuChE levels in the serum of a patient who had accidentally ingested parathion, an organophosphate cholinesterase inhibitor [12].…”

Section: Introductionmentioning

confidence: 99%

Clinical Study on the Effect of Simvastatin on Butyrylcholinesterase Activity

Muačević‐Katanec¹,

Bradamante

²

,

Reiner

³

et al. 2011

Arzneimittelforschung

View full text Add to dashboard Cite

Summary Although the physiological function of serum butyrylcholinesterase (BuChE) has not yet been clarified, there is evidence that this enzyme is involved in serum lipoprotein metabolism. It has been suggested that serum BuChE is positively correlated with LDL (low-density lipoprotein) and negatively with HDL (high-density lipoprotein) levels. The objective of this study was to determine whether the activity of BuChE changes during treatment with simvastatin (CAS 79902-63-9). The effects of simvastatin therapy on serum lipoproteins and plasma BuChE activity were studied in 15 patients with type IIa and 17 patients with type IIb hyperlipoproteinemia. Beside the expected influence on serum lipid concentration, a statistically significant decrease in BuChE activity in patients with hyperli-poproteinemia type IIa and IIb during treatment with simvastatin was not observed.

show abstract

Pseudocholinesterase and serum lipoproteins

Cited by 9 publications

References 8 publications

Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?

Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?

Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?

Clinical Study on the Effect of Simvastatin on Butyrylcholinesterase Activity

Contact Info

Product

Resources

About